Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women

摘要: Objective: The objective of this study was to provide evidence that the transformation DHEA into both androgens and/or estrogens locally in cells three layers vagina (epithelium, lamina propria, and muscularis) would have effects greater impact, including on sexual function, than only superficial epithelial as achieved with estrogens. Methods: This prospective, randomized, double-blind, placebo-controlled phase III clinical trial has evaluated effect daily local intravaginal application Prasterone (dehydroepiandrosterone; DHEA) for 12 weeks domains dysfunction, namely, desire/interest, arousal, orgasm, pain at activity, 216 postmenopausal women moderate severe symptoms vaginal atrophy. Results: A time- dose-dependent improvement four function observed. At 12-week time interval, 1.0% dose led, compared placebo, 49% (P = 0.0061) 23% 0.0257) improvements desire Menopause Specific Quality Life Abbreviated Sex Function questionnaires, respectively. Compared arousal/sensation domain improved by 68% 0.006), arousal/lubrication 39% 0.0014), orgasm 75% 0.047), dryness during intercourse 57% 0.0001). Conclusions: By a action vagina, applied doses which serum steroids remain well within normal values exerts relatively potent beneficial all aspects dysfunction. Such data indicate combined androgenic/estrogenic stimulation important without systemic brain other extravaginal tissues.